Silence Therapeutics plc SEC filings SLN
Silence Therapeutics plc has 275 filings in SEC EDGAR's recent list, going back to Jan 5, 2010. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (material agreement, regulation fd disclosure).
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 5, 2026 | — |
| DEFA14A | Additional proxy material | Oct 19, 2026 | — |
| DEFA14A | Additional proxy material | Oct 19, 2026 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 19, 2026 | Oct 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 13, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 13, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 13, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2026 | — |
| 4 | Insider transaction | Aug 13, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 12, 2026 | Aug 10, 2026 |
| 424B5 | Prospectus supplement | Aug 12, 2026 | — |
| S-3MEF | Filing | Aug 11, 2026 | — |
| 424B5 | Prospectus supplement | Aug 10, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 16, 2026 | Jul 10, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 8, 2026 | — |
| 4 | Insider transaction | Jul 7, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 23, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Other events
|
Jun 11, 2026 | Jun 11, 2026 |
| EFFECT | Filing | May 27, 2026 | — |
| 424B5 | Prospectus supplement | May 27, 2026 | — |
| CORRESP | Letter to the SEC | May 22, 2026 | — |
| UPLOAD | Letter from the SEC | May 22, 2026 | — |
| 8-K |
Current report
Material agreement, Agreement ended, Other events
|
May 18, 2026 | May 18, 2026 |
| S-3 | Shelf registration | May 18, 2026 | — |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 29, 2026 | Jun 16, 2026 |
| S-8 | Employee stock plan registration | Mar 5, 2026 | — |
| 10-K | Annual report | Mar 5, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 5, 2026 | Mar 5, 2026 |
| 4 | Insider transaction | Feb 13, 2026 | Aug 3, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 9, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 9, 2026 | — |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 6, 2026 | Jan 2, 2026 |
| CORRESP | Letter to the SEC | Dec 31, 2025 | — |
| 4 | Insider transaction | Dec 22, 2025 | Dec 18, 2025 |
| 4 | Insider transaction | Dec 22, 2025 | Dec 22, 2025 |
| 3 | Initial insider ownership | Dec 22, 2025 | Dec 14, 2025 |
| 8-K/A |
Amended current report
Officer or director change
|
Dec 22, 2025 | Dec 14, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 22, 2025 | Dec 18, 2025 |
| UPLOAD | Letter from the SEC | Dec 18, 2025 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 15, 2025 | Dec 14, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Other events
|
Oct 23, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 14, 2025 | Aug 11, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 4 | Insider transaction | Aug 4, 2025 | Jul 31, 2025 |
| 4 | Insider transaction | Jul 31, 2025 | Jul 29, 2025 |
| 4 | Insider transaction | Jul 23, 2025 | Jul 21, 2025 |
| 4 | Insider transaction | Jul 16, 2025 | Jul 11, 2025 |
| 4 | Insider transaction | Jul 10, 2025 | Jul 7, 2025 |
| 4 | Insider transaction | Jun 30, 2025 | Jun 26, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 27, 2025 | Jun 26, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jun 25, 2025 | — |
| 4 | Insider transaction | Jun 25, 2025 | Jun 22, 2025 |
| 4 | Insider transaction | Jun 20, 2025 | Jun 17, 2025 |
| 4 | Insider transaction | Jun 13, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | May 29, 2025 | May 26, 2025 |
| 4 | Insider transaction | May 27, 2025 | May 22, 2025 |
| 4 | Insider transaction | May 21, 2025 | May 18, 2025 |
| 4 | Insider transaction | May 20, 2025 | May 5, 2025 |
| 3 | Initial insider ownership | May 20, 2025 | May 5, 2025 |
| ARS | Annual report to shareholders | May 16, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | May 16, 2025 | Jun 26, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| 4 | Insider transaction | May 15, 2025 | May 13, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 8, 2025 | — |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 4 | Insider transaction | May 8, 2025 | May 5, 2025 |
| PRE 14A | Preliminary proxy statement | May 6, 2025 | Jun 26, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 6, 2025 | May 5, 2025 |
| 4 | Insider transaction | May 2, 2025 | Apr 30, 2025 |
| 10-K/A | Amended annual report | Apr 30, 2025 | Dec 31, 2024 |
| 4 | Insider transaction | Apr 30, 2025 | Apr 28, 2025 |
| 4 | Insider transaction | Apr 28, 2025 | Apr 24, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 24, 2025 | — |
| 4 | Insider transaction | Apr 24, 2025 | Apr 22, 2025 |
| 4 | Insider transaction | Apr 22, 2025 | Apr 17, 2025 |
| 4 | Insider transaction | Apr 15, 2025 | Apr 10, 2025 |
| 4 | Insider transaction | Apr 1, 2025 | Mar 31, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 31, 2025 | — |
| 4 | Insider transaction | Mar 31, 2025 | Mar 27, 2025 |
| 4 | Insider transaction | Mar 6, 2025 | Mar 5, 2025 |
| S-8 | Employee stock plan registration | Feb 27, 2025 | — |
| 10-K | Annual report | Feb 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Feb 27, 2025 | Feb 27, 2025 |
| 4 | Insider transaction | Feb 25, 2025 | Jan 8, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 11, 2025 | — |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 3 | Initial insider ownership | Jan 2, 2025 | Jan 2, 2025 |
| 3 | Initial insider ownership | Jan 2, 2025 | Jan 2, 2025 |
| 3 | Initial insider ownership | Jan 2, 2025 | Jan 2, 2025 |
| 3 | Initial insider ownership | Jan 2, 2025 | Jan 2, 2025 |
| 3 | Initial insider ownership | Jan 2, 2025 | Jan 2, 2025 |
| 3 | Initial insider ownership | Jan 2, 2025 | Jan 2, 2025 |
| 3 | Initial insider ownership | Jan 2, 2025 | Jan 2, 2025 |
| 3 | Initial insider ownership | Jan 2, 2025 | Jan 2, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 2, 2025 | Jan 2, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 20, 2024 | — |
| 6-K | Current report (foreign issuer) | Dec 9, 2024 | Dec 9, 2024 |
| 6-K | Current report (foreign issuer) | Nov 18, 2024 | Nov 18, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| 6-K | Current report (foreign issuer) | Nov 14, 2024 | Sep 30, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 12, 2024 | — |
| F-3ASR | Filing | Oct 22, 2024 | — |
| 6-K | Current report (foreign issuer) | Aug 15, 2024 | Jun 30, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Aug 2, 2024 | — |
| 6-K | Current report (foreign issuer) | Jun 27, 2024 | Jun 27, 2024 |
| 6-K | Current report (foreign issuer) | Jun 24, 2024 | Jun 24, 2024 |
| 6-K | Current report (foreign issuer) | Jun 20, 2024 | Jun 20, 2024 |
| 6-K | Current report (foreign issuer) | May 17, 2024 | May 17, 2024 |
| 6-K | Current report (foreign issuer) | May 16, 2024 | Mar 31, 2024 |
| EFFECT | Filing | May 14, 2024 | — |
| 424B3 | Prospectus | May 14, 2024 | — |
| CORRESP | Letter to the SEC | May 10, 2024 | — |
| UPLOAD | Letter from the SEC | May 10, 2024 | — |
| DEL AM | Filing | May 8, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | May 7, 2024 | — |
| 6-K | Current report (foreign issuer) | May 1, 2024 | May 1, 2024 |
| 6-K | Current report (foreign issuer) | Apr 29, 2024 | Apr 29, 2024 |
| 6-K | Current report (foreign issuer) | Apr 15, 2024 | Apr 15, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Mar 27, 2024 | — |
| 20-F | Annual report (foreign issuer) | Mar 13, 2024 | Dec 31, 2023 |
| 6-K | Current report (foreign issuer) | Mar 13, 2024 | Mar 13, 2024 |
| 6-K | Current report (foreign issuer) | Feb 23, 2024 | Feb 23, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 9, 2024 | — |
| 6-K | Current report (foreign issuer) | Feb 6, 2024 | Feb 5, 2024 |
| 6-K | Current report (foreign issuer) | Dec 1, 2023 | Dec 1, 2023 |
| 6-K | Current report (foreign issuer) | Nov 14, 2023 | Nov 14, 2023 |
| 6-K | Current report (foreign issuer) | Nov 1, 2023 | Nov 1, 2023 |
| SC 13G | Ownership over 5% (passive) | Sep 1, 2023 | — |
| 6-K/A | Filing | Aug 29, 2023 | Aug 29, 2023 |
| 6-K | Current report (foreign issuer) | Aug 16, 2023 | Aug 16, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Aug 14, 2023 | — |
| S-8 | Employee stock plan registration | Aug 1, 2023 | — |
| 6-K | Current report (foreign issuer) | Jul 11, 2023 | Jul 11, 2023 |
| 6-K | Current report (foreign issuer) | Jul 3, 2023 | Jul 3, 2023 |
| 6-K | Current report (foreign issuer) | May 16, 2023 | Mar 31, 2023 |
| 6-K | Current report (foreign issuer) | May 4, 2023 | May 4, 2023 |
| 6-K | Current report (foreign issuer) | May 1, 2023 | May 1, 2023 |
| 6-K | Current report (foreign issuer) | Apr 27, 2023 | Apr 27, 2023 |
| 6-K | Current report (foreign issuer) | Mar 28, 2023 | Mar 28, 2023 |
| 20-F | Annual report (foreign issuer) | Mar 15, 2023 | Dec 31, 2022 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 8, 2023 | — |
| 6-K | Current report (foreign issuer) | Jan 12, 2023 | Jan 12, 2023 |
| 6-K | Current report (foreign issuer) | Nov 10, 2022 | Nov 10, 2022 |
| 6-K | Current report (foreign issuer) | Nov 7, 2022 | Nov 7, 2022 |
| SC 13D/A | Amended ownership over 5% (active) | Oct 20, 2022 | — |
| 6-K | Current report (foreign issuer) | Sep 29, 2022 | Sep 29, 2022 |
| SC 13G | Ownership over 5% (passive) | Aug 22, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Aug 19, 2022 | — |
| 6-K | Current report (foreign issuer) | Aug 16, 2022 | Aug 16, 2022 |
| 424B5 | Prospectus supplement | Aug 12, 2022 | — |
| 6-K | Current report (foreign issuer) | Aug 12, 2022 | Aug 12, 2022 |
| 6-K | Current report (foreign issuer) | Aug 11, 2022 | Aug 11, 2022 |
| SC 13D/A | Amended ownership over 5% (active) | Jul 20, 2022 | — |
| SC 13D | Ownership over 5% (active) | Jun 15, 2022 | — |
| 6-K | Current report (foreign issuer) | Jun 14, 2022 | Jun 14, 2022 |
| 6-K | Current report (foreign issuer) | May 16, 2022 | May 16, 2022 |
| 6-K | Current report (foreign issuer) | May 16, 2022 | May 16, 2022 |
| 6-K | Current report (foreign issuer) | Apr 25, 2022 | Apr 25, 2022 |
| 6-K | Current report (foreign issuer) | Apr 4, 2022 | Apr 4, 2022 |
| 6-K | Current report (foreign issuer) | Mar 23, 2022 | Mar 23, 2022 |
| 20-F | Annual report (foreign issuer) | Mar 17, 2022 | Dec 31, 2021 |
| 6-K | Current report (foreign issuer) | Feb 22, 2022 | Feb 22, 2022 |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 10, 2022 | — |
| 6-K | Current report (foreign issuer) | Feb 9, 2022 | Feb 9, 2022 |
| SC 13G | Ownership over 5% (passive) | Feb 7, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Jan 27, 2022 | — |
| 6-K | Current report (foreign issuer) | Dec 13, 2021 | Dec 13, 2021 |
| 6-K | Current report (foreign issuer) | Nov 26, 2021 | Nov 26, 2021 |
| 6-K | Current report (foreign issuer) | Nov 16, 2021 | Nov 16, 2021 |
| 6-K | Current report (foreign issuer) | Nov 1, 2021 | Nov 1, 2021 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SLN (Nasdaq), SLNCF (OTC)
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1479615
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.